• If you are wondering whether West Pharmaceutical Services at US$302.89 is still a sensible entry point or a stock to be cautious about, the valuation is the key question to focus on.
• The share price is down 7.1% over the past week, yet up 10.7% over the last month, 9.6% year to date and 40.3% over the past year. These moves can change how the market views both its potential and its risks.
• These swings come as the stock continues to attract attention in the healthcare equipment and services space, where investors often weigh defensiveness against growth expectations. Together with its longer term returns of a 13.1% decline over three years and an 8.0% decline over five years, this mix of shorter term strength and longer term weakness gives important context before looking at price versus value.
• Right now, West Pharmaceutical Services scores 0 out of 6 on Simply Wall St's valuation checks. The next sections will walk through what different valuation approaches say about the stock and then finish with a broader framework that can help you make more sense of those numbers.

West Pharmaceutical Services scores just 0/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: West Pharmaceutical Services Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting future cash flows and then discounting those cash flows back to today using a required rate of return.

For West Pharmaceutical Services, the model uses a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month Free Cash Flow is about $364.37 million. Analysts provide estimates for the next few years, and Simply Wall St extends those projections further. By 2029, Free Cash Flow is projected at $630 million, with ten year projections ranging from about $445.67 million in 2026 to $856.83 million in 2035, all in $.

After discounting these projected cash flows back to today, the DCF model produces an estimated intrinsic value of $207.98 per share. Compared with the current share price of $302.89, this implies the stock is considered 45.6% above the DCF estimate, so on this measure it screens as expensive.

Result: OVERVALUED

Our Discounted Cash Flow (DCF) analysis suggests West Pharmaceutical Services may be overvalued by 45.6%. Discover 51 high quality undervalued stocks or create your own screener to find better value opportunities.

Approach 2: West Pharmaceutical Services Price vs Earnings

For a profitable company like West Pharmaceutical Services, the P/E ratio is a useful way to relate what you pay for the stock to the earnings the business is currently generating. Investors typically accept a higher P/E when they expect stronger growth or see lower risk, while a lower P/E often reflects more modest growth expectations or higher perceived risk.

West Pharmaceutical Services currently trades on a P/E of 39.43x. That sits above the Life Sciences industry average P/E of 34.39x and also above the peer group average of 23.49x, which suggests the stock is priced at a premium compared with many similar companies.

Simply Wall St's Fair Ratio for West Pharmaceutical Services is 20.12x. This is a proprietary estimate of what the P/E might be based on factors such as the company’s earnings growth profile, industry, profit margins, market cap and specific risks. Because it adjusts for these company level drivers, the Fair Ratio can be more informative than a simple comparison with industry or peer averages. Set against the current P/E of 39.43x, the Fair Ratio points to the stock trading well above this tailored reference point.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your West Pharmaceutical Services Narrative

Earlier it was mentioned that there is an even better way to think about valuation, so this is where Narratives come in as your way to link West Pharmaceutical Services' story to a financial forecast and then to a fair value that fits your own view.

A Narrative is simply your story for the company, where you spell out what you think happens to revenue, earnings and margins, and then connect those assumptions to an estimated fair value instead of relying only on headline ratios like the current P/E of 39.43x or the analyst consensus fair value of about US$349.85.

On Simply Wall St's Community page, which is used by millions of investors, Narratives are an easy tool that let you compare your fair value with the current price so you can judge for yourself whether West Pharmaceutical Services looks attractive, fully priced or expensive based on your own assumptions.

Because Narratives are updated when new information such as earnings, guidance or news on items like the US$1.0b buyback, contract services expansion or CEO transition is added, you can see how your story, your forecast and your fair value move as the facts change.

For example, one investor might build a higher growth Narrative that lines up closer to the upper analyst price target of US$400.00. Another might focus more on risks and sit nearer the lower target of US$310.00, and both can use those fair values next to the current share price to decide what actions, if any, feel appropriate for their own portfolio.

Do you think there's more to the story for West Pharmaceutical Services? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.